$8.35
-0.01-0.12%
最終更新: Sep 30, 7:28 PM
$8.35
-0.01-0.12%
Benzinga
Benzinga
Benzinga
木曜日, 10 01
Benzinga
© 2026 Benzinga | All Rights Reserved
OptimizeRx (OPRX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
OptimizeRx (OPRX) は、8 12, 2026日にfiscal yearの2026に関するガイダンスを直近で発表しました。同社は当期の売上高を$95M - $100Mの範囲と予想しています。
以前のガイダンスと比較して、OptimizeRxは売上高予測を以前の範囲である維持から$95M - $100Mに引き上げました。
OptimizeRxは、15から11 8, 2022の間に8 12, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 8 times and lowered it 4 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.09 | $-0.02 | $0.18 | $-0.01 |
| Actual | $0.16 | $0.14 | $0.51 | $0.20 |
| Surprise | +77.8% | +800.0% | +183.3% | +2100.0% |
| Revenue | ||||
| Estimate | $20.3M | $18.4M | $31.2M | $23.7M |
| Actual | $20.5M | $19.8M | $32.2M | $26.1M |
| Surprise | +1.21% | +8.01% | +3.39% | +10.1% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.15 | $0.40 | $0.09 | $0.12 |
| Revenue | ||||
| Consensus | $21.7M | $34.6M | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $0.16 | $0.09 | 77.8 % |
| Q1 | May 12, 2026 | $0.14 | $-0.02 | 800.0 % |
| Q4 | Mar 5, 2026 | $0.51 | $0.18 | 183.3 % |
| Q3 | Nov 6, 2025 | $0.20 | $-0.01 | 2100.0 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $20.50M | $20.26M | 1.21 % |
| Q1 | May 12, 2026 | $19.84M | $18.37M | 8.01 % |
| Q4 | Mar 5, 2026 | $32.24M | $31.18M | 3.39 % |
| Q3 | Nov 6, 2025 | $26.07M | $23.67M | 10.1 % |